APO 131 (Carbidopa and levodopa extended release 25 mg / 100 mg)
Pill imprint APO 131 has been identified as Carbidopa and levodopa extended release 25 mg / 100 mg.
Carbidopa/levodopa is used in the treatment of parkinson's disease; neuroleptic malignant syndrome; gtp-ch deficiency; restless legs syndrome and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 25 mg / 100 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for APO 131 (Carbidopa and levodopa extended release 25 mg / 100 mg)
- Imprint:
-
APO 131
- Strength:
- 25 mg / 100 mg
- Color:
- Red
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Dopaminergic antiparkinsonism agents
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Apotex Corp.
- National Drug Code (NDC):
- 60505-0131
| NDC Code | Manufacturer / Repackager |
|---|---|
| 00904-5749 | Major Pharmaceuticals |
Note: Inactive ingredients may vary.
More resources
Carbidopa and levodopa extended release is associated with the treatment of:
Search by Imprint, Shape or Color
Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...
